P-134: Older age does not attenuate hypertrophy regression during antihypertensive treatment in hypertensive patients with left ventricular hypertrophy (the life study)
Aging is associated with cardiac remodeling and hypertrophy in hypertensive patients, but less is known about the influence of age on changes in left ventricular (LV) mass and geometry during antihypertensive treatment. We related age to clinical and echocardiographic findings before and after four...
Gespeichert in:
| Veröffentlicht in: | American journal of hypertension 2003-05, Vol.16 (S1), p.87A-87A |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 87A |
|---|---|
| container_issue | S1 |
| container_start_page | 87A |
| container_title | American journal of hypertension |
| container_volume | 16 |
| creator | Gerdts, Eva Roman, Mary J. Palmieri, Vittorio Smith, Gunnar Wachtell, Kristian Nieminen, Markku S. Dahlöf, Björn Devereux, Richard B. |
| description | Aging is associated with cardiac remodeling and hypertrophy in hypertensive patients, but less is known about the influence of age on changes in left ventricular (LV) mass and geometry during antihypertensive treatment. We related age to clinical and echocardiographic findings before and after four years of antihypertensive treatment in a subset of 592 hypertensive patients without concurrent disease in the Losartan Intervention For Endpoint reduction in hypertension study in which patients were randomized to blinded losartan or atenolol based treatment. Patients ≥ 65 years (older group, n=311) included more women and patients with isolated systolic hypertension or albuminuria (all p< 0.05). Compared to patients < 65 years, older patients had higher pulse pressure (PP), LV mass/body surface area and prevalence of concentric hypertrophy at baseline (78 versus 69 mmHg, 127 versus 116 g/m2, and 30 versus 15 %, respectively, all p |
| doi_str_mv | 10.1016/S0895-7061(03)00299-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_istex</sourceid><recordid>TN_cdi_proquest_journals_1026589902</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2712901081</sourcerecordid><originalsourceid>FETCH-LOGICAL-i662-f4d33e16a177ae6814f2d99a0c601c8e37c4edb344166ca638c401e47edcb6043</originalsourceid><addsrcrecordid>eNpVjUFLw0AUhBdRsFZ_gvDASz1E32a3m8SbVK2KUNEexEtYk5d2Nd3E3U21_8ifaaEi9DTMzMcMY8cczzhydf6MaTaMElR8gOIUMc6yiO-wHs8kj5I4Hu6y3j-yzw68f0dEqRTvsZ_HiAt5AZO6JAd6RlA25ME2AXQIZDsdCOarllxwTTtfgaOZI-9NY6HsnLEz0DaYDUHWmyVBcKTDgmwAY2GraXUw69zDlwlzqKkKsFx7Z4qu1m7rZxDmBLWpCHzoytXpIdurdO3p6E_7bHpzPR3dRg-T8d3o8iEySsVRJUshiCvNk0STSrms4jLLNBYKeZGSSApJ5ZuQkitVaCXSQiInmVBZvCmUos9ONrOtaz478iF_bzpn1485x1gN0yzDeE1FG8r4QN9568xCu1Wu3UeuEpEM89uX1_z-6n70NJ6-5Ch-AbfLgt0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1026589902</pqid></control><display><type>article</type><title>P-134: Older age does not attenuate hypertrophy regression during antihypertensive treatment in hypertensive patients with left ventricular hypertrophy (the life study)</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Gerdts, Eva ; Roman, Mary J. ; Palmieri, Vittorio ; Smith, Gunnar ; Wachtell, Kristian ; Nieminen, Markku S. ; Dahlöf, Björn ; Devereux, Richard B.</creator><creatorcontrib>Gerdts, Eva ; Roman, Mary J. ; Palmieri, Vittorio ; Smith, Gunnar ; Wachtell, Kristian ; Nieminen, Markku S. ; Dahlöf, Björn ; Devereux, Richard B.</creatorcontrib><description><![CDATA[Aging is associated with cardiac remodeling and hypertrophy in hypertensive patients, but less is known about the influence of age on changes in left ventricular (LV) mass and geometry during antihypertensive treatment. We related age to clinical and echocardiographic findings before and after four years of antihypertensive treatment in a subset of 592 hypertensive patients without concurrent disease in the Losartan Intervention For Endpoint reduction in hypertension study in which patients were randomized to blinded losartan or atenolol based treatment. Patients ≥ 65 years (older group, n=311) included more women and patients with isolated systolic hypertension or albuminuria (all p< 0.05). Compared to patients < 65 years, older patients had higher pulse pressure (PP), LV mass/body surface area and prevalence of concentric hypertrophy at baseline (78 versus 69 mmHg, 127 versus 116 g/m2, and 30 versus 15 %, respectively, all p<0.01), while mean blood pressure (BP) did not differ. Over 4 years, the reductions in LV mass index and mean BP were similar while PP reduction was larger in the older group (13 versus 11 mmHg, p<0.05). However, more patients in the older group had residual LV hypertrophy (32 versus 16%, p<0.001) with a preponderance of eccentric geometry. In multivariate analysis of 4-year change in LV mass, controlling for baseline LV mass, larger LV mass reduction was associated with female gender and losartan treatment, while age and reduction in body mass index and PP did not enter (Multiple R2=0.39, p<0.001). Thus, in hypertensive patients below 80 years of age with electrocardiographic LV hypertrophy, age does not significantly influence echocardiographic LV mass reduction over 4 years antihypertensive treatment, although residual LV hypertrophy is more prevalent in the older patients as a consequence of higher initial LV mass.]]></description><identifier>ISSN: 0895-7061</identifier><identifier>EISSN: 1941-7225</identifier><identifier>DOI: 10.1016/S0895-7061(03)00299-1</identifier><identifier>CODEN: AJHYE6</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>age ; Hypertension ; hypertrophy regression</subject><ispartof>American journal of hypertension, 2003-05, Vol.16 (S1), p.87A-87A</ispartof><rights>Copyright Nature Publishing Group May 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Gerdts, Eva</creatorcontrib><creatorcontrib>Roman, Mary J.</creatorcontrib><creatorcontrib>Palmieri, Vittorio</creatorcontrib><creatorcontrib>Smith, Gunnar</creatorcontrib><creatorcontrib>Wachtell, Kristian</creatorcontrib><creatorcontrib>Nieminen, Markku S.</creatorcontrib><creatorcontrib>Dahlöf, Björn</creatorcontrib><creatorcontrib>Devereux, Richard B.</creatorcontrib><title>P-134: Older age does not attenuate hypertrophy regression during antihypertensive treatment in hypertensive patients with left ventricular hypertrophy (the life study)</title><title>American journal of hypertension</title><addtitle>AJH</addtitle><description><![CDATA[Aging is associated with cardiac remodeling and hypertrophy in hypertensive patients, but less is known about the influence of age on changes in left ventricular (LV) mass and geometry during antihypertensive treatment. We related age to clinical and echocardiographic findings before and after four years of antihypertensive treatment in a subset of 592 hypertensive patients without concurrent disease in the Losartan Intervention For Endpoint reduction in hypertension study in which patients were randomized to blinded losartan or atenolol based treatment. Patients ≥ 65 years (older group, n=311) included more women and patients with isolated systolic hypertension or albuminuria (all p< 0.05). Compared to patients < 65 years, older patients had higher pulse pressure (PP), LV mass/body surface area and prevalence of concentric hypertrophy at baseline (78 versus 69 mmHg, 127 versus 116 g/m2, and 30 versus 15 %, respectively, all p<0.01), while mean blood pressure (BP) did not differ. Over 4 years, the reductions in LV mass index and mean BP were similar while PP reduction was larger in the older group (13 versus 11 mmHg, p<0.05). However, more patients in the older group had residual LV hypertrophy (32 versus 16%, p<0.001) with a preponderance of eccentric geometry. In multivariate analysis of 4-year change in LV mass, controlling for baseline LV mass, larger LV mass reduction was associated with female gender and losartan treatment, while age and reduction in body mass index and PP did not enter (Multiple R2=0.39, p<0.001). Thus, in hypertensive patients below 80 years of age with electrocardiographic LV hypertrophy, age does not significantly influence echocardiographic LV mass reduction over 4 years antihypertensive treatment, although residual LV hypertrophy is more prevalent in the older patients as a consequence of higher initial LV mass.]]></description><subject>age</subject><subject>Hypertension</subject><subject>hypertrophy regression</subject><issn>0895-7061</issn><issn>1941-7225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpVjUFLw0AUhBdRsFZ_gvDASz1E32a3m8SbVK2KUNEexEtYk5d2Nd3E3U21_8ifaaEi9DTMzMcMY8cczzhydf6MaTaMElR8gOIUMc6yiO-wHs8kj5I4Hu6y3j-yzw68f0dEqRTvsZ_HiAt5AZO6JAd6RlA25ME2AXQIZDsdCOarllxwTTtfgaOZI-9NY6HsnLEz0DaYDUHWmyVBcKTDgmwAY2GraXUw69zDlwlzqKkKsFx7Z4qu1m7rZxDmBLWpCHzoytXpIdurdO3p6E_7bHpzPR3dRg-T8d3o8iEySsVRJUshiCvNk0STSrms4jLLNBYKeZGSSApJ5ZuQkitVaCXSQiInmVBZvCmUos9ONrOtaz478iF_bzpn1485x1gN0yzDeE1FG8r4QN9568xCu1Wu3UeuEpEM89uX1_z-6n70NJ6-5Ch-AbfLgt0</recordid><startdate>200305</startdate><enddate>200305</enddate><creator>Gerdts, Eva</creator><creator>Roman, Mary J.</creator><creator>Palmieri, Vittorio</creator><creator>Smith, Gunnar</creator><creator>Wachtell, Kristian</creator><creator>Nieminen, Markku S.</creator><creator>Dahlöf, Björn</creator><creator>Devereux, Richard B.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200305</creationdate><title>P-134: Older age does not attenuate hypertrophy regression during antihypertensive treatment in hypertensive patients with left ventricular hypertrophy (the life study)</title><author>Gerdts, Eva ; Roman, Mary J. ; Palmieri, Vittorio ; Smith, Gunnar ; Wachtell, Kristian ; Nieminen, Markku S. ; Dahlöf, Björn ; Devereux, Richard B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i662-f4d33e16a177ae6814f2d99a0c601c8e37c4edb344166ca638c401e47edcb6043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>age</topic><topic>Hypertension</topic><topic>hypertrophy regression</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gerdts, Eva</creatorcontrib><creatorcontrib>Roman, Mary J.</creatorcontrib><creatorcontrib>Palmieri, Vittorio</creatorcontrib><creatorcontrib>Smith, Gunnar</creatorcontrib><creatorcontrib>Wachtell, Kristian</creatorcontrib><creatorcontrib>Nieminen, Markku S.</creatorcontrib><creatorcontrib>Dahlöf, Björn</creatorcontrib><creatorcontrib>Devereux, Richard B.</creatorcontrib><collection>Istex</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American journal of hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gerdts, Eva</au><au>Roman, Mary J.</au><au>Palmieri, Vittorio</au><au>Smith, Gunnar</au><au>Wachtell, Kristian</au><au>Nieminen, Markku S.</au><au>Dahlöf, Björn</au><au>Devereux, Richard B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P-134: Older age does not attenuate hypertrophy regression during antihypertensive treatment in hypertensive patients with left ventricular hypertrophy (the life study)</atitle><jtitle>American journal of hypertension</jtitle><addtitle>AJH</addtitle><date>2003-05</date><risdate>2003</risdate><volume>16</volume><issue>S1</issue><spage>87A</spage><epage>87A</epage><pages>87A-87A</pages><issn>0895-7061</issn><eissn>1941-7225</eissn><coden>AJHYE6</coden><abstract><![CDATA[Aging is associated with cardiac remodeling and hypertrophy in hypertensive patients, but less is known about the influence of age on changes in left ventricular (LV) mass and geometry during antihypertensive treatment. We related age to clinical and echocardiographic findings before and after four years of antihypertensive treatment in a subset of 592 hypertensive patients without concurrent disease in the Losartan Intervention For Endpoint reduction in hypertension study in which patients were randomized to blinded losartan or atenolol based treatment. Patients ≥ 65 years (older group, n=311) included more women and patients with isolated systolic hypertension or albuminuria (all p< 0.05). Compared to patients < 65 years, older patients had higher pulse pressure (PP), LV mass/body surface area and prevalence of concentric hypertrophy at baseline (78 versus 69 mmHg, 127 versus 116 g/m2, and 30 versus 15 %, respectively, all p<0.01), while mean blood pressure (BP) did not differ. Over 4 years, the reductions in LV mass index and mean BP were similar while PP reduction was larger in the older group (13 versus 11 mmHg, p<0.05). However, more patients in the older group had residual LV hypertrophy (32 versus 16%, p<0.001) with a preponderance of eccentric geometry. In multivariate analysis of 4-year change in LV mass, controlling for baseline LV mass, larger LV mass reduction was associated with female gender and losartan treatment, while age and reduction in body mass index and PP did not enter (Multiple R2=0.39, p<0.001). Thus, in hypertensive patients below 80 years of age with electrocardiographic LV hypertrophy, age does not significantly influence echocardiographic LV mass reduction over 4 years antihypertensive treatment, although residual LV hypertrophy is more prevalent in the older patients as a consequence of higher initial LV mass.]]></abstract><cop>Oxford</cop><pub>Oxford University Press</pub><doi>10.1016/S0895-7061(03)00299-1</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0895-7061 |
| ispartof | American journal of hypertension, 2003-05, Vol.16 (S1), p.87A-87A |
| issn | 0895-7061 1941-7225 |
| language | eng |
| recordid | cdi_proquest_journals_1026589902 |
| source | Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | age Hypertension hypertrophy regression |
| title | P-134: Older age does not attenuate hypertrophy regression during antihypertensive treatment in hypertensive patients with left ventricular hypertrophy (the life study) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T18%3A03%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_istex&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P-134:%20Older%20age%20does%20not%20attenuate%20hypertrophy%20regression%20during%20antihypertensive%20treatment%20in%20hypertensive%20patients%20with%20left%20ventricular%20hypertrophy%20(the%20life%20study)&rft.jtitle=American%20journal%20of%20hypertension&rft.au=Gerdts,%20Eva&rft.date=2003-05&rft.volume=16&rft.issue=S1&rft.spage=87A&rft.epage=87A&rft.pages=87A-87A&rft.issn=0895-7061&rft.eissn=1941-7225&rft.coden=AJHYE6&rft_id=info:doi/10.1016/S0895-7061(03)00299-1&rft_dat=%3Cproquest_istex%3E2712901081%3C/proquest_istex%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1026589902&rft_id=info:pmid/&rfr_iscdi=true |